1 Introduction
Nasopharyngeal carcinoma (NPC) is a malignant neoplasm with high
radiosensitivity that has a unique etiology and geographic distribution.
Due to the special anatomical location of the tumor, approximately 70%
of newly diagnosed NPC cases are classified as locoregionally advanced
disease, namely locally advanced nasopharyngeal carcinoma (LANC). NPC
lesions often infiltrate the surrounding area, such as parapharyngeal
space and internal carotid artery[1-2]. Concurrent chemoradiotherapy
(CCRT), with epidermal growth factor receptor (EGFR) inhibitors, is an
effective treatment option for LANC[3].